
Indivumed: A global biopharma partner specializing in individualized cancer therapy and biologic sample analysis.
Indivumed, founded in Hamburg, Germany in 2002, is dedicated to the individualization of cancer therapy through the generation, characterization, and analysis of biological samples from human cancer patients. The company offers screening-ready novel target packages for precision oncology, aiming to advance the discovery and development of novel drugs. Indivumed collaborates with leading cancer clinics in Europe, the US, and Asia, and partners with over 100 biopharma industry entities globally.
Notable figures associated with Indivumed include its founder, Hartmut Juhl, a prominent figure in cancer research. The company has achieved significant milestones, such as establishing partnerships with more than 50 oncology practices in Germany and gaining a global reputation for its contributions to cancer therapy. Indivumed's impact is evident in its commitment to creating precise therapeutic treatments that offer high probabilities of successful therapeutic development, significantly advancing the field of oncology.

Ultivue

Certis Oncology Solutions
certisoncology.com

Personalis
personalis.com

Imvaq Therapeutics

OncoPrecision
oncoprecision.bio

HI-Bio
hibio.com

Caris Life Sciences
carisls.com

Genomind
genomind.com

Umoja Biopharma

INmune Bio
inmunebio.com

SpeciCare
specicare.com
IFM Quattro
ifmthera.com

Novasenta
novasenta.com

Intellimedix
intellimedix.com

IMIDomics
imidomics.com

Empiri
empiricancer.com

OncoResponse

Immunome
immunome.com

RootPath Genomics
rootpath.com
Genetron Health
genetronhealth.com
Indivumed's most recent funding round was for €40M (EUR) in January 2018.
As of Jan 9, 2018, Indivumed has disclosed funding of $47.7M (USD).